Is Obeticholic Acid a Regular Drug and Its Legality

Obeticholic Acid is a liver disease treatment drug widely used abroad. It is mainly used to treat chronic hepatobiliary system diseases such as primary biliary cholangitis (PBC). It is a regular prescription drug approved by the FDA in the United States. It was developed by Intercept Pharmaceuticals and first launched in Europe and the United States. It is an original drug that has undergone strict clinical verification and obtained official permission. It has a clear pharmacological mechanism and safety data basis.

However, as of now, obeticholic acid has not yet received marketing approval from the China National Medical Products Administration (NMPA), so it is not yet a regular prescription drug in China. This means that domestic hospitals and pharmacies are not yet able to provide obeticholic acid, and it cannot be reimbursed through medical insurance. If patients need to use this drug, they can only purchase it overseas, overseas direct mail, or make overseas medical purchases through formal channels.

In the international market, in addition to the original version of obeticholic acid provided by Intercept, there are also generic drugs produced by Mylan Pharmaceuticals in India. These generic versions are basically the same as the original drugs in terms of drug ingredients, dosage and usage, and are more affordable. For example, the price of the Indian Mylan version of obeticholic acid is less than 1,000 yuan per box. Compared with the original drug, it significantly reduces the economic burden and provides patients with a wider range of treatment options.

To sum up, obeticholic acid itself is a legal international drug, but it has not been approved for marketing in China. If patients really need treatment, they should purchase it through compliant channels under the guidance of a professional doctor to ensure that the source of the medicine is reliable, safe and effective, and to avoid legal risks or hidden medication risks caused by self-purchasing. With the acceleration of international new drug approvals, obeticholic acid is expected to enter the domestic market in the future, further improving treatment options for patients with liver diseases.

Reference materials:https://www.drugs.com/

xa0